PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
26535126-2	2015	OBJECTIVE: Assess the efficacy and safety of orally administered naloxegol in patients with prospectively confirmed OIC and LIR.	naloxegol	65-74	CD300c molecule	Homo sapiens	124-127	
27342744-5	2016	This analysis estimates the impact of naloxegol on the health state utility of LIR patients, examines if this utility impact is driven by the change in OIC status, and estimates the utility impact of relief of OIC.	naloxegol	38-47	CD300c molecule	Homo sapiens	79-82	
27342744-11	2016	RESULTS: Compared with placebo, LIR patients treated with naloxegol 25 mg reported a 0.08 improvement in the EQ-5D overall score after 12 weeks of treatment.	naloxegol	58-67	CD300c molecule	Homo sapiens	32-35	
26535126-3	2015	METHODS: We analyzed pooled data from two identical randomized, double-blind, placebo-controlled, Phase 3 trials of naloxegol in patients with non-cancer pain, OIC and LIR in which naloxegol (12.5 mg, n = 240; 25 mg, n = 241) or placebo (n = 239) were administered daily.	naloxegol	116-125	CD300c molecule	Homo sapiens	168-171	
26535126-9	2015	CONCLUSIONS: Naloxegol was efficacious, generally safe and well tolerated in the patients with OIC and LIR, while preserving opioid analgesia.	naloxegol	13-22	CD300c molecule	Homo sapiens	103-106